COVID-19 COVID-19
Conditions
Interventions
Ciclesonide is inhaled three times a day at a dose of 400 microgram once a day for seven consecutive days.
Sponsors
Sugiyama Haruhito
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patient who have given written consent to participate in the study 2) Age is over 20 years old, regardless of gender. 3) SARS-CoV-2 PCR positive 4) Patients who have no apparent pneumonia due to COVID-19 on plain chest radiographs 5) Patients who can be hospitalized during study drug administration (Including accommodation and medical treatment) 6) Patients who can inhale ciclesonide using inhalation assist device
Exclusion criteria
Exclusion criteria: 1) Patients with a history of hypersensitivity to Ciclesonide 2) Except for COVID-19, who have infectious disease or deep mycosis without an effective antibacterial agent 3) Patients using inhaled or oral steroids 4) Patients with fever of 37.5 degrees for 7 days 5) Patients co-administering treatments that may have therapeutic effects on COVID-19 6) Patients who are considered inappropriate for inclusion in the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pneumonia incidence on day 8 of ciclesonide inhalation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Changes in clinical findings 2) Changes in laboratory findings 3) SARS CoV 2 virus genome amount 4) Incidence rates of adverse events | — |
Contacts
Public ContactTerada Junko
Center Hospital of the National Center for Global Health and Medicine
Outcome results
None listed